4554.T
Fuji Pharma Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 1,864.00
+2.53%Sep 18, 2026, 09:43 UTC
Fuji Pharma obtained manufacturing and marketing approval in Japan for two biosimilar products, ustekinumab BS 130mg intravenous infusion and golimumab BS 50mg subcutaneous autoinjector.
Source:Sep 17, 2026, 22:15 UTC
Fuji Pharma obtained manufacturing and marketing approval for a second biosimilar product in Japan.
Source:Sep 8, 2026, 08:54 UTC
Fuji Pharma announced on September 7, 2026, the launch of 'Fuji Evidence Digest', a new web content for healthcare professionals that delivers medical papers in audio format, featuring AI navigator 'Hotaru' and AI doctor 'Dr. Tateyama'.
Source:Aug 18, 2026, 09:02 UTC
Fuji Pharma announced on August 17 that it obtained manufacturing and marketing approval for four generic drug products of one ingredient, pomalidomide capsules, for relapsed or refractory multiple myeloma.
Source:Aug 12, 2026, 04:10 UTC
Fuji Pharma Co., Ltd. announced that it was certified as a DX Certified Business Operator by Japan's Ministry of Economy, Trade and Industry, effective August 1, 2026.
Source: